Pacific Biosciences Of California Gross Profit Growth & History (PACB)
Pacific Biosciences Of California's gross profit was $45.8M for fiscal 2025.
View full Pacific Biosciences Of California company overviewPacific Biosciences Of California annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $45.8M | $8.5M | +22.79% |
| 2024 | 2024-12-31 | $37.3M | −$15.5M | −29.36% |
| 2023 | 2023-12-31 | $52.8M | $3.7M | +7.64% |
| 2022 | 2022-12-31 | $49.0M | −$9.8M | −16.69% |
| 2021 | 2021-12-31 | $58.9M | $26.3M | +80.74% |
| 2020 | 2020-12-31 | $32.6M | −$2.0M | −5.81% |
| 2019 | 2019-12-31 | $34.6M | $9.5M | +37.77% |
| 2018 | 2018-12-31 | $25.1M | −$9.6M | −27.59% |
| 2017 | 2017-12-31 | $34.7M | −$9.5M | −21.51% |
| 2016 | 2016-12-31 | $44.2M | −$9.3M | −17.38% |
| 2015 | 2015-12-31 | $53.5M | $30.0M | +128.40% |
| 2014 | 2014-12-31 | $23.4M | $17.0M | +264.57% |
| 2013 | 2013-12-31 | $6.4M | $5.5M | +582.87% |
| 2012 | 2012-12-31 | $940,000 | −$12.1M | −92.79% |
| 2011 | 2011-12-31 | $13.0M | $11.4M | +678.61% |
| 2010 | 2010-12-31 | $1.7M | $1.5M | +1140.00% |
| 2009 | 2009-12-31 | $135,000 | — | — |
Pacific Biosciences Of California quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.6M | −$2.0M | −13.93% |
| Q1 2026 | 2026-03-31 | $12.8M | $14.2M | — |
| Q4 2025 | 2025-12-31 | $16.6M | $6.5M | +64.70% |
| Q3 2025 | 2025-09-30 | $15.9M | $5.9M | +58.95% |
| Q2 2025 | 2025-06-30 | $14.7M | $8.7M | +147.29% |
| Q1 2025 | 2025-03-31 | −$1.4M | −$12.7M | — |
| Q4 2024 | 2024-12-31 | $10.1M | $487,000 | +5.09% |
| Q3 2024 | 2024-09-30 | $10.0M | −$7.9M | −44.12% |
| Q2 2024 | 2024-06-30 | $5.9M | −$9.6M | −61.80% |
| Q1 2024 | 2024-03-31 | $11.3M | $1.5M | +15.58% |
| Q4 2023 | 2023-12-31 | $9.6M | $4.4M | +86.21% |
| Q3 2023 | 2023-09-30 | $17.9M | $4.4M | +32.15% |
| Q2 2023 | 2023-06-30 | $15.5M | −$647,000 | −4.00% |
| Q1 2023 | 2023-03-31 | $9.8M | −$4.4M | −31.04% |
| Q4 2022 | 2022-12-31 | $5.1M | −$11.6M | −69.34% |
| Q3 2022 | 2022-09-30 | $13.5M | −$1.8M | −11.83% |
| Q2 2022 | 2022-06-30 | $16.2M | $2.4M | +17.74% |
| Q1 2022 | 2022-03-31 | $14.2M | $1.2M | +9.08% |
| Q4 2021 | 2021-12-31 | $16.8M | $5.4M | +47.06% |
| Q3 2021 | 2021-09-30 | $15.4M | $8.3M | +117.50% |
| Q2 2021 | 2021-06-30 | $13.8M | $7.1M | +107.97% |
| Q1 2021 | 2021-03-31 | $13.0M | $5.5M | +73.30% |
| Q4 2020 | 2020-12-31 | $11.4M | −$1.5M | −11.84% |
| Q3 2020 | 2020-09-30 | $7.1M | $150,000 | +2.17% |
| Q2 2020 | 2020-06-30 | $6.6M | −$3.0M | −31.21% |
| Q1 2020 | 2020-03-31 | $7.5M | $2.4M | +46.34% |
| Q4 2019 | 2019-12-31 | $12.9M | $7.2M | +125.06% |
| Q3 2019 | 2019-09-30 | $6.9M | $3.7M | +116.60% |
| Q2 2019 | 2019-06-30 | $9.6M | $751,000 | +8.47% |
| Q1 2019 | 2019-03-31 | $5.1M | −$2.2M | −29.87% |
| Q4 2018 | 2018-12-31 | $5.7M | −$3.7M | −39.48% |
| Q3 2018 | 2018-09-30 | $3.2M | −$5.0M | −61.20% |
| Q2 2018 | 2018-06-30 | $8.9M | $861,000 | +10.76% |
| Q1 2018 | 2018-03-31 | $7.3M | −$1.6M | −18.36% |
| Q4 2017 | 2017-12-31 | $9.5M | −$1.9M | −16.53% |
| Q3 2017 | 2017-09-30 | $8.2M | −$4.4M | −34.90% |
| Q2 2017 | 2017-06-30 | $8.0M | −$2.6M | −24.83% |
| Q1 2017 | 2017-03-31 | $8.9M | −$567,000 | −5.97% |
| Q4 2016 | 2016-12-31 | $11.4M | −$15.1M | −57.02% |
| Q3 2016 | 2016-09-30 | $12.6M | $6.1M | +92.92% |
| Q2 2016 | 2016-06-30 | $10.6M | −$3.9M | −26.62% |
| Q1 2016 | 2016-03-31 | $9.5M | $3.6M | +60.35% |
| Q4 2015 | 2015-12-31 | $26.5M | $22.0M | +496.35% |
| Q3 2015 | 2015-09-30 | $6.6M | −$6.6M | −50.23% |
| Q2 2015 | 2015-06-30 | $14.5M | $11.4M | +364.04% |
| Q1 2015 | 2015-03-31 | $5.9M | $3.3M | +121.49% |
| Q4 2014 | 2014-12-31 | $4.4M | $1.2M | +39.17% |
| Q3 2014 | 2014-09-30 | $13.2M | $11.9M | +960.60% |
| Q2 2014 | 2014-06-30 | $3.1M | $2.1M | +195.18% |
| Q1 2014 | 2014-03-31 | $2.7M | $1.7M | +187.74% |
| Q4 2013 | 2013-12-31 | $3.2M | $2.6M | +408.61% |
| Q3 2013 | 2013-09-30 | $1.2M | $1.1M | +553.16% |
| Q2 2013 | 2013-06-30 | $1.1M | $784,000 | +285.09% |
| Q1 2013 | 2013-03-31 | $930,000 | $1.1M | — |
| Q4 2012 | 2012-12-31 | $627,000 | −$910,000 | −59.21% |
| Q3 2012 | 2012-09-30 | $190,000 | −$3.1M | −94.29% |
| Q2 2012 | 2012-06-30 | $275,000 | −$7.6M | −96.52% |
| Q1 2012 | 2012-03-31 | −$152,000 | −$422,000 | — |
| Q4 2011 | 2011-12-31 | $1.5M | — | — |
| Q3 2011 | 2011-09-30 | $3.3M | $3.1M | +1412.73% |
| Q2 2011 | 2011-06-30 | $7.9M | $7.3M | +1155.80% |
| Q1 2011 | 2011-03-31 | $270,000 | — | — |
| Q3 2010 | 2010-09-30 | $220,000 | — | — |
| Q2 2010 | 2010-06-30 | $629,000 | — | — |
Pacific Biosciences Of California gross profit trends
Over the last five fiscal years, Pacific Biosciences Of California's gross profit increased from $32.6M to $45.8M, a change of $13.2M. The latest reported quarter, Q2 2026, shows $12.6M.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pacific Biosciences Of California source filings ↗